Classical Hodgkin lymphoma (cHL) is a malignant lymphoid disorder characterized by aberrant activation of signaling pathways. Constitutive activation of several components of the Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) pathway has been observed in Hodgkin and Reed/Sternberg cells, the tumor cells of cHL. In this study, we investigate the function of STAT6 in cHL cell lines and show that STAT6 promotes survival of these cells. Microarray expression analysis of STAT6-shRNA (short hairpin RNA)-expressing cHL cell lines was carried out to analyze the STAT6-mediated survival mechanism. Some of the identified genes with potentially important regulatory functions were also interleukin (IL)-4 dependently regulated in Ramos B cells and binding of STAT6 to the regulatory regions of several genes could be confirmed, indicating that these are direct STAT6 target genes. Importantly, STAT6 knockdown increased the expression and activation of STAT1 as well as the expression of known STAT1 target genes, indicating a cross-regulation between these signaling molecules. Forced expression of STAT1 was able to induce apoptosis in cHL cell line L1236. These findings indicate that both STAT6 and STAT1 can act as important antagonistic regulators in the pathogenesis of cHL.
Introduction
Classical Hodgkin lymphoma (cHL) is characterized by the presence of a malignant cell population consisting of mononucleated Hodgkin cells and multinucleated Reed-Sternberg (HRS) cells. 1, 2 The tumor cells of cHL represent only about 1% of the tumor mass, whereas the bulk is reactive infiltrate composed of eosinophils, histiocytes, plasma cells, lymphocytes and stromal cells. Although HRS cells are derived from germinal-center B cells indicated by the expression of rearranged immunoglobulin genes, somatic hypermutation and crippled immunoglobulin, they lack the expression of typical B-cell-lineage markers. [3] [4] [5] Recent findings indicate that aberrant expression of transcription regulators that mediate intrinsic inhibition of the B-cell-specific transcription factor, E2A, can cause an extensive reprograming of neoplastic B cell in cHL. 6 However, although a large variety of secondary molecular aberration has been defined for cHL, no cHL-specific transforming event has been identified.
HRS cells as well as the infiltrating cells express high amounts of cytokines including interleukin (IL)-5, IL-6, IL-7, IL-9, IL-10, IL-13 and granulocyte-macrophage colony-stimulating factor. Autocrine and paracrine cytokine secretion is believed to contribute to lymphoma cell survival and proliferation. 7, 8 Aberrant activation of Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signaling in cHL is believed to result from abnormal cytokine expression. In addition, genetic defects that affect positive and negative regulators of this signaling pathway might also lead to the constitutive activation of several STAT proteins. [9] [10] [11] STAT3, STAT5 and STAT6 were shown to be constitutively activated in cHL cell lines as well as in tissue samples of tumor patients. 7, 9, [12] [13] [14] Both STAT3 and STAT5 are regulators of cell proliferation and survival, which are often constitutively activated in various tumors and hematological disorders. 15, 16 STAT3 has already been described as an essential oncogenic factor for cHL cells, as knockdown of STAT3 with specific inhibitors or short hairpin RNAs (shRNAs) results in a decreased proliferation and induction of apoptosis in cHL cell lines. 9, 17 STAT5 may also contribute to Hodgkin lymphomagenesis, as ectopic expression of a constitutive active mutant of STAT5 in primary human B cells resulted in immortalization and modification to large multinucleated cells. Certainly, it has to be clarified to what extent these cells correspond to HRS cells. 18 The function of other activated STATs in cHL is less clear. STAT6 is activated by IL-13, a cytokine that can support cHL cell survival. 19 However, IL-13 can also activate STAT3 and STAT5. 20 In this study, we investigate the function of STAT6 in two cHL cell lines using lentiviral-delivered STAT6-specific shRNAs. Knockdown of STAT6 led to enhanced apoptosis in both cHL cell lines, but with a more dramatic effect in L1236 cells. To elucidate the mechanism how STAT6 prevents apoptosis in cHL and to identify relevant STAT6 target genes, a large-scale gene expression profiling of STAT6-shRNA-expressing L1236 cells was carried out. A large number of up-and downregulated genes were identified, among which there are genes related to apoptosis, cell cycle, transformation and immune response. The STAT6-dependent regulation of selected new STAT6 target genes was confirmed by quantitative (q) reverse transcription-PCR (RT-PCR). Part of these genes was also found to be regulated in an STAT6-dependent manner in L428 cells. In addition, IL-4-dependent regulation in a non-Hodgkin lymphoma cell line and recruitment of STAT6 to potential regulatory regions support the fact that some of these genes are direct STAT6 target genes. Intriguingly, we observed also an increased expression and activation of STAT1 in STAT6-shRNA-expressing cells but not in control cells. To prove the relevance of STAT1 in STAT6-shRNA-induced apoptosis, STAT1 was overexpressed in the cHL cell line L1236. This approach also resulted in enhanced apoptosis, indicating that both STAT1 and STAT6 are involved in the regulation of apoptosis in L1236 cells. Our data indicate that STAT1 and STAT6 are cross-regulated and act in an antagonistic manner in cHL cell line L1236.
Materials and methods

Cell lines and culture conditions
The Hodgkin lymphoma cell lines L428 21 and L1236, 22 as well as Ramos cells from Burkitt lymphoma 23 were grown in RPMI 1640 medium supplemented with 10% fetal calf serum, 2 nM L-glutamine and penicillin/streptomycin.
Plasmids and viral infection
The lentiviral vector pVIG (derived from K Ü berla, Bochum Germany) and the packaging plasmids Dsp2 24 and pHIT-G 25 were kindly provided by K Brocke-Heidrich (University Hospital Leipzig, Germany). The STAT6-shRNA sequence was kindly provided by J Rippman (Boehringer-Ingelheim, Germany).
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STAT6-shRNA coding sequences (given in Supplementary Table  1) were cloned together with the H1 Polymerase III RNA gene promoter into the pVIG vector. The STAT1 sequence was amplified by PCR and cloned behind the spleen focus-forming virus promoter of pVIG. Transfection of packaging cells and transduction of lymphoma cells were performed as described earlier. 9 
Flow cytometry
To examine lentiviral transduction efficiencies, expression of green fluorescent protein was monitored. Cell-cycle analysis of ethanol-fixed cells was carried out using propidium iodide staining as described earlier. 27 Annexin V-APC (BD Pharmingen, Heidelberg, Germany) was used for early apoptosis detection. Samples were analyzed using FACS Calibur with CellQuest Pro Software and FACSCanto using Diva Software (BD Biosciences, Heidelberg, Germany). The FACS analysis shown represents one out of three independently performed experiments.
Cell viability assay
Proliferation was determined using CellTiter-Glo Bioluminescent Assay (Promega, Mannheim, Germany) according to the manufacturer's protocols.
Preparation of lysates and immunoblotting
Cells were lysed in the RIPA (radioimmunoprecipitation assay) buffer (0.12 M NaCl, 0.5% desoxycholate, 0.1% sodium dodecyl sulfate (SDS), 0.05 M Tris-HCl (pH 8), 1 mM sodium orthovanadate, 10 mM NaP 2 O 7 , 1 mM Pefabloc, 1% Triton X-100, 0.1 mM benzamidine, 0.1 mM dithiothreitol and 10 mg/ml of each aprotinin, pepstatin and leupeptin).
Protein extracts (60 mg) were subjected to SDS-polyacrylamide gel electrophoresis and analyzed by western blot analysis. ECL plus Western blotting Detection System (GE Healthcare, Munich, Germany) was used for visualization. The following antibodies were used: STAT1 (sc-346) and STAT3 (sc-482) from Santa Cruz Biotechnology (Heidelberg, Germany), phospho-STAT1 (Tyr701, #9171) from Cell Signaling (Frankfurt, Germany), STAT5 (S21520) and STAT6 (#611290) from Transduction Laboratories (Heidelberg, Germany), and actin (#A2066) and tubulin (#T5168) from Sigma (Munich, Germany). The western blot analysis shown represent one out of three independently performed experiments.
Quantitative RT-PCR
Total cellular RNA was extracted using TriFast (Peqlab, Erlangen, Germany) according to the manufacturer's protocol. Aliquots of total cellular RNA (2 mg) were subjected to firststrand cDNA synthesis using Omniscript Reverse Transcriptase (Qiagen, Hilden, Germany). For transcript quantification, the iQ5 Real Time PCR Cycler (Bio-Rad, Munich, Germany) and Absolute QPCR SYBR Green Master Mix (Thermo, Dreieich, Germany) were used. mRNA levels were normalized against endogenous 18S mRNA. Sequences of primers used for PCR are given in Supplementary 
DNA microarray analysis and pathway analysis
Total RNA was prepared from L1236 cells transduced with STAT6-and scrambled-shRNA-expressing lentiviral vectors 72 h after transduction when efficient downregulation of STAT6 could be detected by western blot analysis in parallel and when 20-40% of the STAT6-shRNA-expressing cells were apoptotic. Samples for Human Genome Survey (V2.0) hybridization were prepared according to Applied Biosystems (Darmstadt, Germany) instructions. Data analysis was carried out using the Expression Array System Software (Version 1.1.1; Applied Biosystems) and the Spotfire Decision Site Software, Spotfire DecisionSite 8.1 (Spotfire, Palo Alto, CA, USA). The quality of all microarrays was as recommended by Applied Biosystems. A list of differentially expressed genes was prepared by using the unpaired t-statistic. The following genes are excluded in the final differentially expressed gene list: Genes that are differentially expressed (Pp0.05, fold change X2 or pÀ2) between noninfected L1236 and scrambled-shRNA-transduced cells. Furthermore, genes that have a Flag value X5000 are excluded according to the Applied Biosystems 1700 Chemiluminescent Microarray AnalyzerFUser Guide. A detailed description of the data analysis is given in Supplementary Information. The analysis was carried out with two independent biological replicates.
Pathway analysis and analysis of over-represented genes with distinct molecular functions were carried out based on PANTHER (Protein ANalysis THrough Evolutionary Relationships) database of protein function and pathways. 28 
Chromatin immunoprecipitation
Cells (5 Â 10 6 cells per immunoprecipitation (IP)) were crosslinked with a final concentration of 1% formaldehyde and incubated for 10 min at room temperature. Crosslinking was stopped by the addition of glycin to a final concentration of 100 mM. The cells were washed two times with cold phosphatebuffered saline and re-suspended in 150 ml of the lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris, pH 8.1) per IP, and incubated on ice for 10 min followed by sonification (four times for 10 s each time at amplitude maximum of 50% using a Branson 250 D 
Results and discussion
Knockdown of STAT6 induces apoptotic cell death in cHL cell lines IL-13, a regulator of STAT6 activation, is frequently expressed in cHL and regulates cell proliferation and apoptosis in cHL cell lines. 7, 29 Moreover, a soluble IL-13Ralpha2 decoy receptor inhibits cHL growth in vitro and in vivo. 30 However, as IL-13 can also activate other signaling pathways and STAT family members, this approach is not sufficient to prove the function of STAT6 in lymphomagenesis. To investigate the specific functions of STAT6, we stably expressed shRNAs against STAT6 by lentiviral transduction in the cHL cell lines, L428 and L1236. Transduction efficiencies (B80%) were confirmed by the FACS analysis on the basis of green fluorescent protein co-expression (data not shown). Non-targeting (scrambled) shRNAs were used as a control. To confirm downregulation of STAT6, western blot analysis was carried out 72 h after transduction. Two shRNAs targeting distinct sites in STAT6 (shSTAT6A and shSTAT6B) were tested and both were able to downregulate STAT6 in L428 and L1236 cells, although with different efficiency (Figure 1a) . Expression of STAT3 and STAT5 was as expected, not affected by STAT6-specific shRNAs (Supplementary Figure 1) .
To examine the effect of STAT6 depletion on the proliferation of cHL cells, cell-cycle profiles were obtained by flow cytometry using propidium iodide staining. This analysis showed an increased amount of cells in the sub-G1 population in both cell lines transduced with different STAT6-shRNAs as compared with scrambled shRNA-expressing cells (Figure 1b) . The values of the G1 and G2 cell populations were not affected, indicating that knockdown of STAT6 has the strongest effect on cell survival and does not induce cell-cycle arrest. This effect was more pronounced in L1236 cells as compared with L428 cells, although shRNA-mediated downregulation was even more efficient in L428 cells. To investigate whether apoptosis is involved in this process, we performed Annexin V staining of both cell lines transduced with the most powerful STAT6-shRNA. We detected increased levels of Annexin V-positive cells in STAT6-shRNA-expressing cells in comparison with the cells transduced with the scrambled control (Supplementary Figure 2) . Similar to the cell-cycle profile, Annexin V staining showed more apoptotic cell death in L1236 cells when compared with the L428 cells, indicating that L1236 cells are more dependent on STAT6 signaling for survival. Treatment of transduced L1236 cells with the pan-Caspase inhibitor, Z-VAD-FMK, prevented cell death, thus further confirming that STAT6-shRNA-expressing cells die by apoptosis (Figure 1c) .
Taken together, our results clearly show that STAT6 acts as a survival factor in cHL cell lines, although it seems to be of different importance in the cell lines analyzed. As also STAT3 and STAT5 have been described as essential regulators of proliferation and survival of cHL cells, 9, 17, 18 cHL cells are essentially dependent on several transcription factors from this signaling pathway.
STAT6-dependent gene profiling in L1236 cells
Our analysis so far implies that the presence of STAT6 inhibits apoptosis in cHL cell lines. To determine the STAT6-mediated anti-apoptotic signaling and to identify essential STAT6 target genes, a gene expression profiling was performed. As L1236 cells were more sensitive in our analysis, we chose this cell line for further experiments. This cell line has been characterized as a Reed-Sternberg-derived cell line 4, 22 and is therefore the best model cell line available.
STAT6-shRNA-and scrambled-shRNA-expressing L1236 cells were subjected to microarray analysis (for details, see Material and methods). For data analysis, genes that were found to be differentially expressed between control-shRNA transduced and untransduced cells were deleted to exclude genes induced by virus infection itself. A total of 641 genes including 255 unknown genes met the criteria that expression was considered as decreased or increased upon depletion of STAT6 in L1236 cells with a fold change of 42 in each of the independent duplicates (Supplementary Table 2 ). A list of the 386 known genes differentially regulated in response to STAT6 depletion is given in Supplementary Information. It is interesting that more of these genes were upregulated than downregulated after STAT6 depletion in L1236 cells. Our data are consistent with a recent study on the gene expression of IL-4-stimulated B cells from STAT6-deficient mice, where also more genes were found to be expressed at higher levels and support that STAT6 can act as a positive as well as a negative regulator of gene expression. 31 Classical STAT6 target genes such as CD23 or IL4R were not affected in our analysis. Only few of the genes had already been described as IL-4-regulated genes in normal B cells stimulated by IL-4 32 and are direct STAT6 targets in other cells. 33 This suggests that constitutive activation of STAT6 in cHL leads to the expression of a different set of transcriptionally regulated genes. In addition, the specific autocrine cytokine milieu found in cHL cells could influence gene expression of STAT6 target genes. 18, 34 Simultaneous activation of several STAT family members and other important survival factors such as nuclear factor-kB might also influence the transcriptional regulation by STAT6. 35 Next, the ontology of the identified genes based on the molecular function, pathway and biological process was analyzed using the PANTHER Protein Classification System (Supplementary Table 3 ) to identify functional annotations that Antagonistic function of STAT6 and STAT1 in cHL D Baus et al were significantly enriched in the STAT6-dependent regulated genes. This analysis showed that the genes involved in signaling and with regulatory functions, such as cytokine receptors, kinase inhibitors and modulators, were over-represented. As expected, the IL signaling pathway and the JAK/STAT signaling pathway were significantly represented. Although genes involved in several enzymatic functions and pathways, including cysteine proteases and ubiquitin protein ligases, were identified to be enriched, no specific oncogenesis associated and apoptosisregulating pathways were identified by this analysis.
Some of the STAT6-dependent genes are essential regulators
To prove our experimental design, we focused on a selection of 20 genes out of the 386 differentially regulated known genes ( Figure 2 ). These genes were selected based on their potential regulatory function in important cellular processes, including regulation of proliferation, apoptosis or invasiveness with the preference on genes with high rate of fold change after STAT6 depletion. In accordance with the pathway analysis (Supplementary Table 3 ), we also included regulators of immune response and ubiquitin pathway in our analysis.
STAT6-dependent regulation of these genes could be confirmed by the qRT-PCR analysis of scrambled versus STAT6-shRNA-expressing L1236 cells (Figure 2a) . As the presence of STAT6 protects L1236 cells from apoptotic cell death, we expected apoptosis-related genes to be differentially expressed in a STAT6-dependent manner. Indeed, increased expression of the pro-apoptotic genes, CASP7, TNFSF10 and XAF1, was detected in L1236 cells after STAT6 knockdown and was confirmed by qRT-PCR. In addition to the upregulated genes with pro-apoptotic function, we identified and confirmed a number of genes with anti-apoptotic or tumor-promoting functions with decreased expression after STAT6 depletion. These include CDK6, a member of the cyclin-dependent protein kinase family, MYC, a known oncogene and EPHB1 (a tyrosine kinase receptor already known to be expressed and activated in HRS cells from cHL patients but not in normal B cells. 36 It is interesting that, PTPRC (CD45), a JAK phosphatase, which negatively regulates cytokine signaling, is upregulated after STAT6 depletion, indicating that STAT6 could repress the expression of this essential regulator of B-lymphocyte maturation. 37 Another group of genes with decreased expression after STAT6 depletion belongs to the ubiquitin pathway, suggesting a role of STAT6 in regulating the proteasomal degradation system, which is essential in cHL cells. 38 Taken together, we identified a number of new potential STAT6 target genes in cHL cells, which themselves have important functions in cellular processes and are involved in the regulation of survival and proliferation in several cells and tissues.
We next analyzed whether STAT6-dependent regulation of the selected genes could also be detected in L428 cells that exhibit a better viability in response to STAT6 depletion (Figure 1b) . Out of the 20 selected genes, 12 were also STAT6-dependent regulated in L428 cells, even though the fold regulation that was detected by qRT-PCR was always lower. Interestingly, two of the apoptosis regulators (CASP7 and TNFSF10/TRAIL) are directly opposed regulated in L428 and L1236 cells (Figure 2b) . The different regulation of these genes in both cHL cell lines seems to display the well-known heterogeneousness of the cHL cell lines. 39 Moreover, L1236 and L428 cells are derived from different cHL subtypes (mixed cellularity and nodular sclerosis, respectively), which express a different set of tyrosine kinase receptors. 36 This might affect the STAT6-dependent regulation that is modified by additional signaling pathways, for example, the mitogen-activated protein kinase pathway. 40 Although the majority of the genes are regulated in both cell lines, different regulation of apoptosis regulators might reflect different sensitivity of the cells to shSTAT6-induced apoptosis.
Some of the novel STAT6-dependent genes in cHL cells are inducible by IL-4
As also transcription factors, such as NFAT5 and EOMES, were affected by STAT6 depletion (Figure 2) , we wondered whether the identified genes are direct STAT6 target genes. For further verification, we analyzed whether the identified potential new STAT6 target genes can also be regulated by transient STAT6 activation. Such analysis could not be carried out in cHL cell lines in which STAT6 is already constitutively phosphorylated. 9 We used, therefore, Ramos Burkitt lymphoma cells where IL-4 stimulation leads to transient STAT6 activation (data not shown). About one-third of the selected genes were also regulated by the IL-4 signaling pathway in this non-Hodgkin lymphoma cell line. The regulation (activation versus repression) corresponds to the results obtained in the STAT6-eliminated cHL cell line L1236 (Figures 3a and b) . For the other genes, no regulation was observed (for example, PARP9, UBE2D4, IPO4), or they were regulated in a different direction (for example, XAF1, GBP1, TRIM22, CDK6, STAT1) or could not be detected at all at significant levels (for example, TNFSF10, RARRES3, AIM2, EOMES) (data not shown).
Although we performed our experiments after 4, 6, 14 and 24 h IL-4 induction, we cannot exclude that the non-responsive genes might be affected at different time points. Otherwise, the regulation of these genes might require constitutive STAT6 activation or the presence of other transcription factors that are activated in cHL, such as nuclear factor-kB or activator protein 1.
41,42
STAT6 recruitment to regulatory regions of novel STAT6 target genes Direct transcriptional regulation of the identified genes by STAT6 should require the binding of STAT6 to a conserved binding element. We therefore carried out a recognition site analysis for putative STAT and STAT6 binding sites by the MatInspector program (Genomatix, Munich, Germany). For CASP7, PTPRC (CD45), EPHB, USP2 and NFAT5, we could Table 4) . Next, ChIP assays were performed in L1236 cells to detect the binding of STAT6 to the putative binding sites. The precipitated chromatin was analyzed by qPCR using primer pairs flanking the putative binding sites and as control primer pairs flanking regions at least 1000 bp downstream of the transcriptional start site, where no STAT6 binding side had been detected. In all cases, we were able to precipitate chromatin fragments containing the putative STAT6 binding sites at higher amounts by STAT6 antibody as compared with the control precipitation by IgG (Figure 4b ). In addition, lower amounts of the control chromatin fragments without STAT binding sites were precipitated, supporting that STAT6 specifically binds to the proposed binding sites. Detailed analysis of further binding sites is currently carried out and preliminary results indicate that STAT6 can bind to several sites in the identified genes.
STAT6 depletion leads to the activation of STAT1 and STAT1 target genes
Our initial gene expression profiling of STAT6-shRNA-expressing cHL cell line showed strong activation of numerous genes related to interferon (IFN)-mediated immunity (Figure 2 and  Supplementary Tables 2 and 3 ). Strongest induction was observed for GBP1, TRIM22 and AIM2, which are already described as IFN-responsive genes. Similarly, STAT1, the mediator of IFN signaling, and IFN genes themselves are activated in response to STAT6 depletion in L1236 cells (Supplementary Table 2 ). As STAT1 is an essential regulator of anti-viral response, we at first assumed that infection of the cells with lentiviral vectors or expression of shRNA account for the induction of these genes. However, no induction was observed when cells were transduced with scrambled-shRNA-expressing lentiviral vector, indicating that the observed effect is specific and depends on the downregulation of STAT6. As STAT1 mediates inhibition of proliferation and induction of apoptosis in several cell systems, it could be an indirect mediator of apoptosis induction after STAT6 depletion. 43, 44 To test this hypothesis, we analyzed the induction of STAT1 in response to STAT6 depletion by western blot analysis. Knockdown of STAT6 led to the induction of STAT1 on RNA and protein levels (Figures 5a and b) . This was accompanied by an increase in the activated, phosphorylated form of STAT1 as determined by phospho-STAT1-specific antibody. Lentiviral expression of scrambled-shRNA neither affected STAT1 expression nor the activation of STAT1, confirming that the activation of STAT1 was not merely induced by viral infection or shRNA expression.
Overexpression of STAT1 induces apoptosis in cHL cell line L1236
To investigate whether STAT1 contributes to apoptosis of cHL cells depleted of STAT6, we overexpressed STAT1 in L1236 cells by a lentiviral vector (Figure 6a) . The increased amount of Cellcycle analysis of the STAT1 overexpressing cells showed an increase in the sub-G1 population as compared with cells transduced with an empty vector, suggesting an induction of apoptosis in these cells. This was further confirmed by the addition of the pan-caspase inhibitor Z-VAD-FMK, which reduced the sub-G1 population to the levels similar to the control transduced cells (Figure 6c ). Taken together, we show that inhibition of STAT6 results in the induction of apoptosis in cHL cell lines. We identified a number of new potential STAT6 target genes in cHL cells with important functions in the regulation of proliferation and apoptosis. The heterogeneity of cHL might prevent that all of the identified genes are STAT6-dependent regulated in either case as already observed for a cHL cell line derived from a different cHL subtype. However, some of the genes might contribute to the STAT6-mediated survival of the cells. Besides the identification of new potential STAT6 target genes with apoptosis-related functions, we could show an interplay of STAT6 and STAT1 in cHL cells. Strikingly, STAT6 depletion by shRNA enhanced STAT1 expression and activation, as well as induction of several well-known STAT1 target genes. Nuclear expression of STAT1 had been detected in HRS cells by immunohistochemistry. 45 We would expect that the amount of STAT1 contribute to the decision on apoptotic cell death. Our present data suggest that constitutively active STAT6 inhibits STAT1 expression and activation in cHL. To prove whether this model applies to cHL, we will analyze the activation state of Antagonistic function of STAT6 and STAT1 in cHL D Baus et al STAT6 and the amount of STAT1 expression in parallel by immunohistochemistry of primary HRS cells. It has already been described that IL-4-stimulated STAT6 is able to repress STAT1 function and vice versa IFN-activated STAT1 inhibits STAT6. 46, 47 The mechanism for this is not fully understood but involves transcriptional activation by STAT6. A cross-talk between STAT6 and STAT1 can be mediated by SOCS1, which is a target of both STATs and acts as a negative regulator of IFN signaling. 48 However, the SOCS1 gene is often mutated in HRS cells, and overexpression of SOCS1 did not affect the proliferation of L1236 cells. 9, 10 These observations argue against a function of SOCS1 in the STAT6/STAT1 interplay in cHL. Although we could not yet discover the mechanism how STAT6 depletion enhances STAT1 expression and activation, suppression of STAT1 seems to be important for the survival of cHL cells as overexpression of STAT1 leads to an induction of apoptosis in L1236 cells. This might be mediated by STAT1-regulated target genes, which we found to be expressed at higher levels in our microarray of STAT6-depleted L1236 cells. In summary, all these results support that STAT6 and STAT1 are essential oppositional regulators of apoptosis, at least in distinct, cHL subtypes.
